文献速递系统性红斑狼疮血管炎类风湿关节炎

人源化效应缺失FcγRIIA抗体抑制免疫复合物介导的促炎反应

Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses.
PubMed 文献 · Ann Rheum Dis · 2018-11-20

本研究旨在开发并表征首创新型抗FcγRIIA抗体VIB9600,该抗体阻断IgG免疫复合物介导的细胞活化。体外实验显示VIB9600抑制pDC产生I型干扰素、中性粒细胞产生活性氧及TNFα和IL-6产生;在FcγRIIA转基因小鼠中抑制血小板减少、肾炎和关节炎;在食蟹猴中展现良好药代动力学和安全性。

要点

  • VIB9600通过阻断配体结合及内化FcγRIIA抑制免疫复合物介导的激活。
  • 体外抑制SLE、ANCA相关血管炎和RA相关促炎反应。
  • 在FcγRIIA转基因小鼠中抑制血小板减少、肾炎和关节炎。

核心结论

  • VIB9600是特异性人源化FcγRIIA拮抗抗体,效应功能缺失,值得进一步临床开发用于免疫复合物介导疾病。

研究设计与样本

  • 从IV.3抗体人源化优化获得VIB9600,通过Biacore和ELISA测定亲和力与特异性。
  • 采用共聚焦显微镜、流式细胞术和结合竞争实验评估作用机制,体外细胞实验验证抑制免疫复合物介导炎症反应。
  • 在FcγRIIA转基因小鼠中验证靶点抑制和疗效,在非人灵长类中进行单剂量药代动力学/药效学研究及多剂量GLP毒性研究。

主要发现

  • VIB9600通过阻断配体结合和内化FcγRIIA抑制FcγRIIA激活。
  • VIB9600抑制pDC受免疫复合物诱导产生I型干扰素(参与SLE)。
  • VIB9600抑制ANCA诱导中性粒细胞产生活性氧(参与ANCA相关血管炎)。
  • VIB9600抑制免疫复合物诱导TNFα和IL-6产生(参与RA)。
  • 在FcγRIIA转基因小鼠中,VIB9600抑制抗血小板抗体诱导血小板减少、急性抗GBM抗体诱导肾炎和抗胶原抗体诱导关节炎;在食蟹猴中展现良好PK和安全性。

关键数值与推荐

  • VIB9600抑制pDC产生I型干扰素、中性粒细胞产生ROS及TNFα和IL-6产生。
  • 在FcγRIIA转基因小鼠中抑制血小板减少、肾炎和关节炎。
  • 在食蟹猴中展现良好药代动力学和安全性特征。

临床怎么用

  • VIB9600作为FcγRIIA拮抗抗体,可能用于治疗免疫复合物介导的自身免疫病如SLE、ANCA相关血管炎和RA。
  • 需进一步临床开发验证其疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune complexes (ICs) play a critical role in the pathology of autoimmune diseases. The aim of this study was to generate and characterise a first-in-class anti-FcγRIIA antibody (Ab) VIB9600 (previously known as MEDI9600) that blocks IgG immune complex-mediated cellular activation for clinical development. METHODS: VIB9600 was humanised and optimised from the IV.3 Ab. Binding affinity and specificity were determined by Biacore and ELISA. Confocal microscopy, Flow Cytometry-based assays and binding competition assays were used to assess the mode of action of the antibody. In vitro cell-based assays were used to demonstrate suppression of IC-mediated inflammatory responses. In vivo target suppression and efficacy was demonstrated in FcγRIIA-transgenic mice. Single-dose pharmacokinetic (PK)/pharmacodynamic study multiple dose Good Laboratory Practice (GLP) toxicity studies were conducted in non-human primates. RESULTS: We generated a humanised effector-deficient anti-FcγRIIA antibody (VIB9600) that potently blocks autoantibody and IC-mediated proinflammatory responses. VIB9600 suppresses FcγRIIA activation by blocking ligand engagement and by internalising FcγRIIA from the cell surface. VIB9600 inhibits IC-induced type I interferons from plasmacytoid dendritic cells (involved in SLE), antineutrophil cytoplasmic antibody (ANCA)-induced production of reactive oxygen species by neutrophils (involved in ANCA-associated vasculitis) and IC-induced tumour necrosis factor α and interleukin-6 production (involved in rheumatoid arthritis). In FcγRIIA transgenic mice, VIB9600 suppressed antiplatelet antibody-induced thrombocytopaenia, acute anti-GBM Ab-induced nephritis and anticollagen Ab-induced arthritis. VIB9600 also exhibited favourable PK and safety profiles in cynomolgus monkey studies. CONCLUSIONS: VIB9600 is a specific humanised antibody antagonist of FcγRIIA with null effector function that warrants further clinical development for the treatment of IC-mediated diseases.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Chen B, Vousden KA, Naiman B, et al. Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses. Ann Rheum Dis. 2018. PMID: 30459279. doi:10.1136/annrheumdis-2018-213523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。